Ocugen Inc (OCGN)

$1.07 0.00 (N/A)
Market Cap 312.77M
Revenue (ttm) 4.06M
Net Income (ttm) -54.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,331.28%
Debt to Equity Ratio 9.19
Volume 1,722,800
Avg Vol 2,656,452
Day's Range N/A - N/A
Shares Out 292.31M
Stochastic %K 100%
Beta 4.15
Analysts Strong Sell
Price Target $6.50

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 328 4701
Address:
11 Great Valley Parkway, Malvern, United States
Skindlo
Skindlo Sep. 14 at 2:48 PM
$OCGN “Regarding the recent 8-K (‘New Agreement’, September 5, 2025), it reports a material event/new agreement. The filing includes forward-looking statements about licensing and deal benefits. Can anyone break down the exact financial and contractual details for this agreement?”
0 · Reply
Tomassso
Tomassso Sep. 14 at 10:45 AM
$OCGN
0 · Reply
luca75
luca75 Sep. 14 at 10:09 AM
$OCGN Anyone have any guesses about when the first quarter of solid positive revenues will come from Ocu400 commercialization? To me that’s when we will start to see real SP appreciation.😎
1 · Reply
Ernesto62
Ernesto62 Sep. 14 at 9:29 AM
$OCGN what will Friday Happen?
0 · Reply
Reacherman
Reacherman Sep. 13 at 11:08 PM
$OCGN Remember Triple Witching Hour is this coming Friday.
0 · Reply
barrrmannn
barrrmannn Sep. 13 at 8:27 PM
$OCGN https://youtu.be/ltQo0llIr5M?si=i75s_M3TjvhAAfry
0 · Reply
The_Beginner
The_Beginner Sep. 13 at 7:45 PM
$OCGN is there any interesting milestone this year?
1 · Reply
HisRoyalHighnessM
HisRoyalHighnessM Sep. 13 at 7:24 PM
$OCGN
0 · Reply
Reacherman
Reacherman Sep. 13 at 5:44 PM
$OCGN I'm back in folks... LFG!
0 · Reply
Djtrush
Djtrush Sep. 13 at 5:05 PM
$OCGN Holding from England
3 · Reply
Latest News on OCGN
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 12 days ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 4 weeks ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 4 weeks ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 5 weeks ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 12:30 PM EDT - 6 weeks ago

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 6 weeks ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 7 weeks ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 2 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 2 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 2 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 18, 2025, 4:00 PM EDT - 3 months ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 3 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 3 months ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 3 months ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 3 months ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:02 AM EDT - 4 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 4 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 4 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 4 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 5 months ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 6 months ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 10:59 AM EST - 6 months ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 6 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 7 months ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 8:00 AM EST - 7 months ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 12, 2025, 7:42 AM EST - 7 months ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Feb 3, 2025, 6:30 AM EST - 7 months ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 27, 2025, 6:30 AM EST - 8 months ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 16, 2025, 7:30 AM EST - 8 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Jan 13, 2025, 6:30 AM EST - 8 months ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 19, 2024, 6:38 AM EST - 9 months ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 11, 2024, 7:02 AM EST - 9 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Nov 27, 2024, 7:09 AM EST - 10 months ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Nov 20, 2024, 7:30 AM EST - 10 months ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Nov 19, 2024, 7:02 AM EST - 10 months ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 10:18 AM EST - 11 months ago

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Nov 8, 2024, 6:45 AM EST - 11 months ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen Secures $30 Million in Debt Funding

Nov 7, 2024, 6:30 AM EST - 11 months ago

Ocugen Secures $30 Million in Debt Funding

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Oct 28, 2024, 6:30 AM EDT - 11 months ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Oct 22, 2024, 7:02 AM EDT - 11 months ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Oct 17, 2024, 7:30 AM EDT - 11 months ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Oct 9, 2024, 6:30 AM EDT - 1 year ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Sep 17, 2024, 2:25 AM EDT - 1 year ago

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Sep 9, 2024, 6:30 AM EDT - 1 year ago

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Skindlo
Skindlo Sep. 14 at 2:48 PM
$OCGN “Regarding the recent 8-K (‘New Agreement’, September 5, 2025), it reports a material event/new agreement. The filing includes forward-looking statements about licensing and deal benefits. Can anyone break down the exact financial and contractual details for this agreement?”
0 · Reply
Tomassso
Tomassso Sep. 14 at 10:45 AM
$OCGN
0 · Reply
luca75
luca75 Sep. 14 at 10:09 AM
$OCGN Anyone have any guesses about when the first quarter of solid positive revenues will come from Ocu400 commercialization? To me that’s when we will start to see real SP appreciation.😎
1 · Reply
Ernesto62
Ernesto62 Sep. 14 at 9:29 AM
$OCGN what will Friday Happen?
0 · Reply
Reacherman
Reacherman Sep. 13 at 11:08 PM
$OCGN Remember Triple Witching Hour is this coming Friday.
0 · Reply
barrrmannn
barrrmannn Sep. 13 at 8:27 PM
$OCGN https://youtu.be/ltQo0llIr5M?si=i75s_M3TjvhAAfry
0 · Reply
The_Beginner
The_Beginner Sep. 13 at 7:45 PM
$OCGN is there any interesting milestone this year?
1 · Reply
HisRoyalHighnessM
HisRoyalHighnessM Sep. 13 at 7:24 PM
$OCGN
0 · Reply
Reacherman
Reacherman Sep. 13 at 5:44 PM
$OCGN I'm back in folks... LFG!
0 · Reply
Djtrush
Djtrush Sep. 13 at 5:05 PM
$OCGN Holding from England
3 · Reply
9long
9long Sep. 13 at 3:25 PM
$OCGN The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. Does this mean they expect the stock price to rise to the $2.50 level within 2 years??? Someone help us amateurs understand these things....
1 · Reply
Babilon1210
Babilon1210 Sep. 13 at 3:06 PM
$OCGN
1 · Reply
Babilon1210
Babilon1210 Sep. 13 at 3:03 PM
$OCGN Catalyst any day now
0 · Reply
Babilon1210
Babilon1210 Sep. 13 at 3:02 PM
$OCGN Im loading at every chance I get
0 · Reply
Pit1908
Pit1908 Sep. 13 at 1:07 PM
$OCGN 🗞️🧬🗞️ This is worth more than $20 a share
1 · Reply
Pit1908
Pit1908 Sep. 13 at 12:48 PM
$OCGN Never give up! 💪🏻 Because one day, your story of resilience will be the light that guides someone else through the storm. 🌪️ Every challenge you overcome today becomes a testimony of hope for those who need it tomorrow! 🙇🏻‍♂️ Remember that you are stronger than you think, and your experience will be an inspiration to many! 🫂 Growth sometimes takes time and dedication. Don't stop cultivating your dreams just because you don't see immediate results. Patience is the key to success. 📈 Keep growing, the fruits will come! 💎👀
0 · Reply
brunomonteiro
brunomonteiro Sep. 13 at 12:16 PM
$OCGN
0 · Reply
brunomonteiro
brunomonteiro Sep. 13 at 12:07 PM
$OCGN
0 · Reply
nick2341
nick2341 Sep. 13 at 11:31 AM
$OCGN not that bad this year till now!
0 · Reply
Babilon1210
Babilon1210 Sep. 13 at 7:43 AM
$OCGN My guess: Next Ocugen partnership: Eli Lilly
1 · Reply
arniezb
arniezb Sep. 13 at 5:57 AM
$OCGN ✅✅♥️♥️
0 · Reply
barrrmannn
barrrmannn Sep. 13 at 12:41 AM
$OCGN groove, muhfuhggs! https://youtu.be/jRIlHDWG9So?si=30ZDMKAeSZ25QfyF
1 · Reply